Atopic Dermatitis and Other Dermatitis (Atopic Dermatitis)
Özet
This chapter focuses on atopic dermatitis (AD) and other dermatitis types in the elderly population, emphasizing their epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment. AD is a chronic inflammatory skin disease whose prevalence and clinical characteristics differ significantly with age. In elderly individuals, physiological skin changes, multimorbidity, and polypharmacy complicate disease management. The chapter discusses the main immunological mechanisms underlying AD, including skin barrier dysfunction, Th2-mediated inflammation, and age-related immune alterations. It also reviews diagnostic challenges due to overlapping pruritic dermatoses and highlights both conventional and emerging treatment options such as topical corticosteroids, calcineurin inhibitors, phototherapy, biologics, and JAK inhibitors. Additionally, other common eczematous disorders of aging—such as irritant and allergic contact dermatitis, seborrheic dermatitis, stasis dermatitis, and xerotic eczema—are reviewed in terms of their pathogenesis, clinical manifestations, and management strategies. Understanding these diseases within the context of geriatric dermatology is crucial for optimizing therapeutic outcomes and improving quality of life in elderly patients, who often face chronic pruritus, comorbidities, and functional limitations.
Referanslar
Sulzberger MB, Goodman J. The relative importance of specific skin hypersensitivity in adult atopic dermatitis. J Am Med Assoc 1936; 106:1000–3.
Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers 2018; 4. doi:10.1038/S41572-018-0001-Z.
Schmitt J, Bauer A, Meurer M. [Atopic exzema in adulthood]. Hautarzt 2008; 59:841–50.
Bieber T BC. Atopic dermatitis. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology (Jorizzo JL SJ, ed), 3rd ed. amsterdam, elsevier, 2012; 203–17.
Tanei R, Hasegawa Y. Atopic dermatitis in older adults: A viewpoint from geriatric dermatology. Geriatr Gerontol Int. 2016; 16:75–86.
Girolomoni G, de Bruin-Weller M, Aoki V, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis 2021; 12. doi:10.1177/20406223211002979.
Williams HC. Epidemiology of atopic dermatitis. Clin Exp Dermatol 2000; 25:522–9.
Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis study - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/8776352/ [accessed on 21 July 2024].
Wolkewitz M, Rothenbacher D, Löw M, et al. Lifetime prevalence of self-reported atopic diseases in a population-based sample of elderly subjects: results of the ESTHER study. Br J Dermatol 2007; 156:693–7.
Bozek A, Fisher A, Filipowska B, et al. Clinical features and immunological markers of atopic dermatitis in elderly patients. Int Arch Allergy Immunol 2012; 157:372–8.
Sybilski AJ, Raciborski F, Lipiec A, et al. Epidemiology of atopic dermatitis in Poland according to the Epidemiology of Allergic Disorders in Poland (ECAP) study. J Dermatol 2015; 42:140–7.
Tanei R, Katsuoka K. Clinical analyses of atopic dermatitis in the aged. J Dermatol 2008; 35:562–9.
Sandström MH, Faergemann J. Prognosis and prognostic factors in adult patients with atopic dermatitis: a long-term follow-up questionnaire study. Br J Dermatol 2004; 150:103–10.
Bannister MJ, Freeman S. Adult-onset atopic dermatitis. Australas J Dermatol 2000; 41:225–8.
Rystedt I. Long term follow-up in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985; 114:117–20.
Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol 1998; 139:834–9.
Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol 2019; 80:1526-1532.e7.
Jaworek AK, Hałubiec P, Kachnic N, et al. Clinical characteristics of elderly patients with atopic dermatitis — a retrospective observational study. Folia Med Cracov 2023; 63:29–40.
Chan LN, Magyari A, Ye M, et al. The epidemiology of atopic dermatitis in older adults: A population-based study in the United Kingdom. PLoS One 2021; 16. doi:10.1371/JOURNAL.PONE.0258219.
Girolomoni G, de Bruin-Weller M, Aoki V, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis 2021; 12. doi:10.1177/20406223211002979.
Tanei R. Clinical Characteristics, Treatments, and Prognosis of Atopic Eczema in the Elderly. J Clin Med 2015; 4:979–97.
Leung DYM, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113:651–7.
Tanei R. Atopic dermatitis in the elderly. Inflamm Allergy Drug Targets 2009; 8:398–404.
Silverberg JI, Margolis DJ, Boguniewicz M, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol 2019; 33:1341–8.
Chello C, Carnicelli G, Sernicola A, et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. Int J Dermatol 2020; 59:716–21.
Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. J Allergy Clin Immunol 2011; 127:1110–8.
Bieber T, D’Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J Allergy Clin Immunol 2017; 139:S58–64.
Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118:152–69.
K J, Y H, Y T, et al. Analysis of beta-glucocerebrosidase and ceramidase activities in atopic and aged dry skin. Acta Derm Venereol 1994; 74:334.
Aoyama H, Tanaka M, Hara M, et al. Nummular eczema: An addition of senile xerosis and unique cutaneous reactivities to environmental aeroallergens. Dermatology 1999; 199:135–9.
Beck LA, Cork MJ, Amagai M, et al. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. JID innovations : skin science from molecules to population health 2022; 2. doi:10.1016/J.XJIDI.2022.100131.
Chiricozzi A, Maurelli M, Calabrese L, et al. Overview of Atopic Dermatitis in Different Ethnic Groups. J Clin Med 2023; 12. doi:10.3390/JCM12072701.
Maurelli M, Chiricozzi A, Peris K, et al. Atopic Dermatitis in the Elderly Population. Acta Derm Venereol. 2023; 103. doi:10.2340/actadv.v103.13363.
Yue W, Cheng D, Sun Z, et al. Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting-based study. Br J Dermatol 2023; 188:420–6.
Liu P, Zhao Y, Mu ZL, et al. Clinical Features of Adult/Adolescent Atopic Dermatitis and Chinese Criteria for Atopic Dermatitis. Chin Med J (Engl) 2016; 129:757–62.
Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int 2022; 71:448–58.
Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol 2017; 139:S49–57.
Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol 2019; 46:1053–101.
Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy 2014; 69:46–55.
Brunner PM, Khattri S, Garcet S, et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2016; 138:169–78.
Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32:657–82.
Papier A, Strowd LC. Atopic dermatitis: a review of topical nonsteroid therapy. Drugs Context 2018; 7. doi:10.7573/DIC.212521.
Zane LT, Kircik L, Call R, et al. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. Pediatr Dermatol 2016; 33:380–7.
Teng Y, Zhong H, Yang X, et al. Current and Emerging Therapies for Atopic Dermatitis in the Elderly. Clin Interv Aging. 2023; 18:1641–52.
Tanei R. Atopic Dermatitis in Older Adults: A Review of Treatment Options. Drugs Aging 2020; 37:149–60.
Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol 2022; 36:1409–31.
Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 2022; 36:1904–26.
Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019; 143:155–72.
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371:130–9.
Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 2021; 35:958–64.
Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184:437–49.
Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 2021; 85:863–72.
Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol 2021; 85:854–62.
Elmariah SB, Smith JS, Merola JF. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety. Am J Clin Dermatol 2022; 23:427–31.
Yoon S, Kim K, Shin K, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2024; 38:52–61.
Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol 2020; 59:e75–91.
Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016; 74:491–8.
Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol 2017; 119:548-552.e3.
Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol 2018; 121:340–7.
Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol 2018; 121:604-612.e3.
Shaheen MS, Silverberg JI. Atopic dermatitis is associated with osteoporosis and osteopenia in older adults. J Am Acad Dermatol 2019; 80:550–1.
He H, Li R, Choi S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis. Ann Allergy Asthma Immunol 2020; 124:70–8.
Effect of elderly status on complications in atopic dermatitis patients. J Am Acad Dermatol 2019; 81:AB50.
Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. J Invest Dermatol 2017; 137:18–25.
Tanei R. Senile atopic dermatitis. Evolution of Atopic Dermatitis in the 21st Century 2017; :229–48.
World Population Prospects The 2017 Revision. .
Caruso C, Buffa S, Candore G, et al. Mechanisms of immunosenescence. Immun Ageing 2009; 6. doi:10.1186/1742-4933-6-10.
Raschke C, Elsner P. Skin Aging: A Brief Summary of Characteristic Changes. Textbook of Aging Skin 2010; :37–43.
Prakash A V., Davis MDP. Contact dermatitis in older adults: a review of the literature. Am J Clin Dermatol 2010; 11:373–81.
Fisher AA., Rietschel RL., Fowler JF. Fisher’s contact dermatitis. 1995; :1117.
Lui H, Alajlan A. Contact & Occupational Dermatology, 3rd ed. Arch Dermatol 2003; 139:1508–1508.
Leonard A, Guttman-Yassky E. The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment. Clin Rev Allergy Immunol 2019; 56. doi:10.1007/S12016-018-8685-0.
Simon M, Bernard D, Minondo AM, et al. Persistence of both peripheral and non-peripheral corneodesmosomes in the upper stratum corneum of winter xerosis skin versus only peripheral in normal skin. J Invest Dermatol 2001; 116:23–30.
Lichterfeld-Kottner A, El Genedy M, Lahmann N, et al. Maintaining skin integrity in the aged: A systematic review. Int J Nurs Stud 2020; 103. doi:10.1016/J.IJNURSTU.2019.103509.
Beele H, Smet S, Van Damme N, Beeckman D. Incontinence-Associated Dermatitis: Pathogenesis, Contributing Factors, Prevention and Management Options. Drugs Aging 2018; 35:1–10.
Fluhr JW, Dickel H, Kuss O, et al. Impact of anatomical location on barrier recovery, surface pH and stratum corneum hydration after acute barrier disruption. Br J Dermatol 2002; 146:770–6.
Löffler H, Effendy I, Happle R. [Irritant contact dermatitis]. Hautarzt 2000; 51:203–18.
Saint-Mezard P, Krasteva M, Chavagnac C, et al. Afferent and efferent phases of allergic contact dermatitis (ACD) can be induced after a single skin contact with haptens: evidence using a mouse model of primary ACD. J Invest Dermatol 2003; 120:641–7.
Zhao Y, Balato A, Fishelevich R, et al. Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis. Br J Dermatol 2009; 161:1301–6.
Carlsen BC, Menné T, Johansen JD. 20 Years of standard patch testing in an eczema population with focus on patients with multiple contact allergies. Contact Dermatitis 2007; 57:76–83.
Önder M, Öztas MO. Contact dermatitis in the elderly. Contact Dermatitis 2003; 48:232–3.
Freireich-Astman M, David M, Trattner A. Standard patch test results in patients with contact dermatitis in Israel: age and sex differences. Contact Dermatitis 2007; 56:103–7.
Green CM, Holden CR, Gawkrodger DJ. Contact allergy to topical medicaments becomes more common with advancing age: an age-stratified study. Contact Dermatitis 2007; 56:229–31.
Wantke F, Hemmer W, Jarisch R, Götz M. Patch test reactions in children, adults and the elderly. A comparative study in patients with suspected allergic contact dermatitis. Contact Dermatitis 1996; 34:316–9.
A retrospective epidemiology study of contact eczema among the elderly attending a tertiary dermatology referral centre in Singapore - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/9885705/ [accessed on 11 August 2024].
Margolis DJ, Bilker W, Santanna J, Baumgarten M. Venous leg ulcer: incidence and prevalence in the elderly. J Am Acad Dermatol 2002; 46:381–6.
Machet L, Couhé C, Perrinaud A, et al. A high prevalence of sensitization still persists in leg ulcer patients: a retrospective series of 106 patients tested between 2001 and 2002 and a meta-analysis of 1975-2003 data. Br J Dermatol 2004; 150:929–35.
Saap L, Fahim S, Arsenault E, et al. Contact sensitivity in patients with leg ulcerations: a North American study. Arch Dermatol 2004; 140:1241–6.
Veien NK. Systemic contact dermatitis. Int J Dermatol 2011; 50:1445–56.
Kulberg A, Schliemann S, Elsner P. Contact dermatitis as a systemic disease. Clin Dermatol 2014; 32:414–9.
Bolognia J, Jorizzo J, Rapini R, et al. Dermatology 2nd edition. 2008.URL https://www.scholars.northwestern.edu/en/publications/dermatology-2nd-edition-2 [accessed on 11 August 2024].
Thomson KF, Wilkinson SM, Powell S, Beck MH. The prevalence of corticosteroid allergy in two U.K. centres: prescribing implications. Br J Dermatol 1999; 141:863–6.
Seborrheic dermatitis: an overview - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/16848386/ [accessed on 11 August 2024].
Diagnosis and treatment of seborrheic dermatitis - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/25822272/ [accessed on 11 August 2024].
Safe and effective treatment of seborrheic dermatitis - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/19681345/ [accessed on 11 August 2024].
Mastrolonardo M, Diaferio A, Vendemiale G, Lopalco P. Seborrhoeic dermatitis in the elderly: inferences on the possible role of disability and loss of self-sufficiency. Acta Derm Venereol 2004; 84:285–7.
Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18:13–26.
Adalsteinsson JA, Kaushik S, Muzumdar S, et al. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol 2020; 29:481–9.
de Avelar Breunig J, de Almeida HL, Duquia RP, et al. Scalp seborrheic dermatitis: prevalence and associated factors in male adolescents. Int J Dermatol 2012; 51:46–9.
Seborrheic dermatitis in neuroleptic-induced parkinsonism - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/6134496/ [accessed on 11 August 2024].
Mastrolonardo M, Diaferio A, Vendemiale G, Lopalco P. Seborrhoeic dermatitis in the elderly: inferences on the possible role of disability and loss of self-sufficiency. Acta Derm Venereol 2004; 84:285–7.
Sowell J, Pena SM, Elewski BE. Seborrheic Dermatitis in Older Adults: Pathogenesis and Treatment Options. Drugs Aging 2022; 39:315–21.
Diagnosis and treatment of seborrheic dermatitis - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/25822272/ [accessed on 11 August 2024].
Gupta AK, Madzia SE, Batra R. Etiology and management of Seborrheic dermatitis. Dermatology 2004; 208:89–93.
Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol 2013; 31:343–51.
Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: a comprehensive review. J Dermatolog Treat 2019; 30:158–69.
FW D, WS M, LJ M, D R. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29:1008–12.
Zouboulis CC. Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol 2006; 126:2154–6.
Ahmad HM. Analysis of clinical efficacy, side effects, and laboratory changes among patients with acne vulgaris receiving single versus twice daily dose of oral isotretinoin. Dermatol Ther 2015; 28:151–7.
Rzepecki AK, Blasiak R. Stasis Dermatitis: Differentiation from Other Common Causes of Lower Leg Inflammation and Management Strategies. Curr Geriatr Rep 2018; 7:222–7.
Sundaresan S, Migden MR, Silapunt S. Stasis Dermatitis: Pathophysiology, Evaluation, and Management. Am J Clin Dermatol. 2017; 18:383–90.
Maffei FHA, Magaldi C, Pinho SZ, et al. Varicose veins and chronic venous insufficiency in Brazil: prevalence among 1755 inhabitants of a country town. Int J Epidemiol 1986; 15:210–7.
Yalçin B, Tamer E, Toy GG, et al. The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. Int J Dermatol 2006; 45:672–6.
Bergan JJ, Schmid-Schönbein GW, Smith PDC, et al. Chronic venous disease. N Engl J Med 2006; 355:488–98.
Jacob MP, Badier-Commander C, Fontaine V, et al. Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 2001; 49:326–32.
Theodosat A. Skin diseases of the lower extremities in the elderly. Dermatol Clin 2004; 22:13–21.
Mehta A, Pereira R, Nayak C, Dhurat R. Acroangiodermatitis of mali: A rare vascular phenomenon. Indian J Dermatol Venereol Leprol 2010; 76:553–6.
Keller EC, Tomecki KJ, Alraies MC. Distinguishing cellulitis from its mimics. Cleve Clin J Med 2012; 79:547–52.
Yosipovitch G, Nedorost ST, Silverberg JI, et al. Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol. 2023; 24:275–86.
Al Shammeri O, Alhamdan N, Al-Hothaly B, et al. Chronic Venous Insufficiency: prevalence and effect of compression stockings. Int J Health Sci (Qassim) 2014; 8:231–6.
Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/22801396/ [accessed on 12 August 2024].
Bielanski TE, Piotrowski ZH. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2012; 11:171–2.
Norman RA. Xerosis and pruritus in the elderly: recognition and management. Dermatol Ther 2003; 16:254–9.
Dermatological Complaints of the Elderly Attending a Dermatology Outpatient Clinic in Turkey: A Prospective Study over a One-year Period - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/26724880/ [accessed on 14 August 2024].
Akimoto K, Yoshikawa N, Higaki Y, et al. Quantitative analysis of stratum corneum lipids in xerosis and asteatotic eczema. J Dermatol 1993; 20:1–6.
Cassler NM, Burris AM, Nguyen JC. Asteatotic eczema in hypoesthetic skin: a case series. JAMA Dermatol 2014; 150:1088–90.
Asteatotic Eczema - PubMed [WWW Document]. URL https://pubmed.ncbi.nlm.nih.gov/31747214/ [accessed on 14 August 2024].
Ng SY, Begum S, Chong SY. Does Order of Application of Emollient and Topical Corticosteroids Make a Difference in the Severity of Atopic Eczema in Children? Pediatr Dermatol 2016; 33:160–4.
Schulz P, Bunselmeyer B, Bräutigam M, Luger TA. Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007; 21:90–4.
